ATHE 6-K
Alterity Therapeutics Ltd (ATHE)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-163
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 13, 2025
Alterity Therapeutics Limited
(Name of Registrant)
Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)
ALTERITY THERAPEUTICS LIMITED
(a development stage enterprise)
The following exhibits are submitted:
| 99.1 | Disclosure under Takeovers Panel GN 20 |
|---|
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Alterity Therapeutics Limited | |
|---|---|
| By: | /s/ Geoffrey<br>P. Kempler |
| Geoffrey P. Kempler | |
| Chairman |
Date: November 13, 2025
2
Exhibit 99.1
| ASX ANNOUNCEMENT | 13 November 2025 |
|---|
Disclosure under Takeovers Panel Guidance
Note 20: Equity Derivatives
Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) (“the Company”) advises that it has received the attached notice from Regal Funds Management Asia Pte Limited which was provided to the Company pursuant to the Australian Takeovers Panel Guidance Note 20 – Equity Derivatives.
Authorised for release by:
Abby Macnish Niven
Company Secretary
Alterity Therapeutics Limited
For further information please contact:
Investors
Remy Bernarda
Investor Relations Advisory Solutions
+1 (415) 203-6386
Alterity Therapeutics Limited ACN 080 699 065
Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
www.alteritytherapeutics.com
12-November-2025
Dear Alterity Therapeutics ltd,
Disclosure of Long Equity Derivative Positions
We refer to Guidance Note 20: Equity Derivatives (GN20), issued by the Australian Takeovers Panel. Terms not defined in this notice have the meanings given to them in GN20.
GN20 relevantly provides that the non-disclosure of long positions, including long equity derivative positions, may give rise to unacceptable circumstances. Regal Funds Management Asia Pte Limited, as investment manager of Amazon Market Neutral Fund and Zambezi Absolute Return Fund (the Funds), discloses the following information on behalf of the Funds.
| Identity of the taker: | Amazon Market Neutral Fund | Zambezi Absolute Return Fund |
|---|---|---|
| Relevant security: | Ordinary shares in Alterity Therapeutics ltd | |
| Price (including reference price, strike price, option price etc as appropriate): | Not applicable | |
| Entry date and number of securities to which the derivative relates: | Total number of securities to which derivatives relate as at 10-Nov-2025: 50,000,000 (0.46%) | Total number of securities to which derivatives relate as at 10-Nov-2025: 503,141,403 (4.63%) |
| Any material changes to information previously disclosed: | No information previously disclosed | Previous disclosure of below 5% on 31-Jul-2024 |
| Relevant interests in securities: | None | |
| Long equity derivative positions and relevant interests held by the taker and its associates: | The Funds have no other associates with a long equity derivative position or relevant interest in the company | |
| Short equity derivative positions that offset physical positions: | None | |
| Short positions of more than 1% that have been acquired after a long position is disclosed, whether by notice or substantial holding notice: | None |
Yours sincerely
| /s/ Greg Laughlin |
|---|
| Greg Laughlin |
Chief Executive Officer
Regal Funds Management Asia Pte Limited
| Regal Funds Management Asia Pte Limited | T +65 6654 1755<br>80 | Raffles Place #26-23 UOB<br>Plaza 2<br><br>Singapore 048624 |
|---|